Downloads
Revenue

Description

I nuovi anticoagulanti orali rappresentano una valida alternativa alla terapia con warfarin nella prevenzione di ictus ed embolia sistemica in pazienti adulti con fibrillazione atriale non valvolare con almeno uno dei fattori di rischio per ictus.
Attualmente i NAO approvati in Europa e negli Stati Uniti sono dabigatran, rivaroxaban, apixaban e edoxaban.
Questa applicazione consente di identificare la prescrivibilità e la posologia di dabigatran, rivaroxaban, apixaban e edoxaban in pazienti adulti con fibrillazione atriale non valvolare.
Hide Show More...

Screenshots

NAO FAQ

  • Is NAO free?

    Yes, NAO is completely free and it doesn't have any in-app purchases or subscriptions.

  • Is NAO legit?

    Not enough reviews to make a reliable assessment. The app needs more user feedback.

    Thanks for the vote

  • How much does NAO cost?

    NAO is free.

  • What is NAO revenue?

    To get estimated revenue of NAO app and other AppStore insights you can sign up to AppTail Mobile Analytics Platform.

User Rating
App is not rated in Spain yet.
Ratings History

NAO Reviews

No Reviews in Spain
App doesn't have any reviews in Spain yet.

Store Rankings

Ranking History
App Ranking History not available yet
Category Rankings
Chart
Category
Rank
Top Free
468

Keywords

NAO Competitors

Name
prepSSM
App di preparazione al SSM
Manuali AIMS
INTERCheck
iFarmaci
Prontuario professionale
Emergency Drugs
Specializzazione Medicina
Supera il Concorso SSM
Farmamico
Antibiotici
CardioTalk
DOAC-INT

NAO Installs

Last 30 days

NAO Revenue

Last 30 days

NAO Revenue and Downloads

Gain valuable insights into NAO performance with our analytics.
Sign up now to access downloads, revenue, and more.

App Info

This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.